Faye Tachibana, MD
Allergy & Immunology · Aiea, HINPI 1245641448
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (55.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Sanofi at 55.0% of the total. Reporting peaked in 2019 at $729 and has fallen 71.4% since, to $209 in 2025.
Across 15 payments — averaging $84.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$700
- Regeneron Healthcare Solutions, Inc.$170
- Grifols USA, LLC$114
- ARS Pharmaceuticals Operations, Inc.$95
- Takeda Pharmaceuticals U.S.A., Inc.$76
- AstraZeneca$55
- plus $64 from 3 others
What the payments were for
- Grants$70055%
- Food & beverage$55744%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $700 |
| Regeneron Healthcare Solutions, Inc. | 3 | $170 |
| Grifols USA, LLC | 1 | $114 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $76 |
| AstraZeneca | 2 | $55 |
| GSK | 1 | $24 |
| Novartis | 1 | $23 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 50 | $205,359 |
| Fasenra PenBenralizumab | 19 | $107,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $104,380 |
| TezspireTezepelumab-Ekko | 20 | $88,192 |
| Dupixent SyringeDupilumab | 19 | $70,983 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $21,724 |
| DuleraMometasone/Formoterol | 22 | $10,110 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,693 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $3,463 |
| BreynaBudesonide/Formoterol Fumarate | 19 | $2,947 |
| Tacrolimus | 13 | $2,738 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,508 |
| Montelukast Sodium | 72 | $2,206 |
| Ipratropium Bromide | 61 | $2,192 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $1,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $55 | $114,60956 claims |
| GSKTrelegy Ellipta | $24 | $104,380132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Aiea
- Marina OstroukhovaHonolulu$158K
- Philip KuoKailua$27K
- Philip KuoKailua$9K
- Abigail HaradaHonolulu$8K
- Kelly ShibuyaHonolulu$7K
- Akila SreedharanHonolulu$6K
- Richard AndoHonolulu$5K
- Matthew LauHonolulu$3K
- Allan WangKailua Kona$2K
- Jennifer MbuthiaHonolulu$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.